Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Anthera Pharmaceuticals Inc.
  • AstraZeneca Plc
  • BIND Therapeutics Inc.
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Celldex Therapeutics Inc.
  • Cerus Corp.
  • CytoSorbents Corp.
  • Incyte Corp.
  • Merck & Co. Inc.
  • Novavax Inc.
  • Omeros Corp.
  • OncoGenex Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmacyclics Inc.
  • Roche Holding AG
  • Verastem Inc.

John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

The Medical Technology Stock Letter has earned the #1 ranking from Hulbert's Financial Digest. >Read More




Recent Interviews

Biotech Watchlist Update: Small-Cap Biotechs Struggle to Rebound (11/6/14) When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance of Streetwise Reports' Biotechnology Watchlist to date reflects this trend: The portfolio lingered in negative territory after the late-winter punch, and hovers near breakeven as of Nov. 3. To get a handle on the drivers of small-cap stock price volatility, The Life Sciences Report turned to a pair of the analysts who selected companies for the 2014 Watchlist, John McCamant of the Medical Technology Stock Letter and George Zavoico of MLV & Co. In this recap, the two experts offer updates on the companies they selected for the portfolio.

Fire Up the Immuno-Oncology Powerhouses: John McCamant (6/19/14) Forecasting when we'll have a cure for cancer remains beyond the predictive powers of researchers and investors. But forecasting the focus of the latest American Society of Clinical Oncology meeting was in the cards: Immuno-oncology took center stage. In this interview with The Life Sciences Report, Medical Technology Stock Newsletter editor John McCamant describes the excitement surrounding this rapidly evolving sector, and names big pharma and small biotech players conjuring potential game-changers.

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (1/15/14) stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

Recent Quotes

"We continue to believe that OGXI is undervalued." (12/21/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence." (10/25/12) Cyclacel Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger." (10/4/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"We continue to believe that OGXI is undervalued." (7/20/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging." (6/8/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"We are pleased OGXI is flexible in its OGX-011 development plans." (3/16/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"OGXI could be a home-run stock." (2/23/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >



Due to permission requirements, not all quotes are shown.